Publication date: Jul 10, 2024
Impaired lung gas exchange is commonly seen in patients with pulmonary involvement related to SARS-CoV-2 acute infection or post-acute COVID-19 syndrome (PACS). The primary aim of our study was to assess lung gas transfer, measuring the pulmonary diffusion capacity for nitric oxide (D) and carbon monoxide (D) in all COVID-19 patients. Our secondary aim was to decipher the respective roles of perturbed lung membrane conductance (D) and reduced pulmonary capillary volume (V) in patients with impaired lung gas exchange. From May to October 2020, we measured D-D in 118 patients during their post-COVID-19 period (4. 6 months after infection) to decipher alveolo-capillary gas transfer disturbances. D-D measurement was also performed in 28 healthy non-smokers as controls. Patients were classified into three groups according to the severity (mild, moderate, and severe) of acute COVID-19 infection. Patients with mild COVID-19 had normal lung volumes and airways expiratory flows but impaired pulmonary gas exchange, as shown by the significant decreases in D, D, D, and V as compared with controls. V was significantly impaired and the D/D ratio was increased in patients with moderate (n = 4, 11%) and severe COVID-19 (n = 23, 49%). Abnormal membrane conductance was also seen in all three groups of post-COVID-19 patients. These findings suggest a persistent alveolo-capillary gas transfer defect, implying not only reduced membrane conductance but also abnormal pulmonary vascular capacitance in all PACS patients, even those with a milder form of COVID-19 infection.
Open Access PDF
| Concepts | Keywords |
|---|---|
| Disease | COVID-19 |
| Milder | lung capillary volume |
| Nitric | nitric oxide |
| Pulmonary | pulmonary diffusion |
| pulmonary function |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | COVID-19 |
| disease | MESH | Lung Disease |
| disease | IDO | acute infection |
| disease | MESH | post-acute COVID-19 syndrome |
| drug | DRUGBANK | Nitric Oxide |
| drug | DRUGBANK | Carbon monoxide |
| disease | VO | volume |
| disease | MESH | infection |
| disease | MESH | vascular capacitance |
| drug | DRUGBANK | L-Citrulline |
| disease | MESH | pneumonia |
| disease | MESH | pulmonary embolism |
| disease | MESH | respiratory distress syndrome |
| disease | MESH | death |
| disease | MESH | chest pain |
| disease | MESH | abnormalities |
| drug | DRUGBANK | Coenzyme M |
| disease | VO | efficiency |
| drug | DRUGBANK | Trestolone |
| disease | MESH | systemic sclerosis |
| disease | MESH | pulmonary hypertension |
| disease | MESH | sarcoidosis |
| disease | MESH | cystic fibrosis |
| disease | VO | population |
| disease | MESH | bronchitis |
| disease | MESH | bacterial pneumonia |
| disease | IDO | history |
| disease | MESH | pulmonary arterial hypertension |
| drug | DRUGBANK | Bentiromide |
| disease | VO | time |
| drug | DRUGBANK | Oxygen |